Targeting GM-CSF in rheumatoid arthritis

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in myeloid cell function and is implicated in rheumatoid arthritis (RA) pathogenesis.
• Preclinical data and clinical observations suggest GM-CSF contributes to RA flares.

Purpose of the Study:

• To evaluate the safety, tolerability, and efficacy of targeting GM-CSF or its receptor in rheumatoid arthritis.
• To assess the potential of mavrilimumab as an alternative biologic agent for RA.

Main Methods:

• Phase II clinical trials of mavrilimumab, a monoclonal antibody targeting the GM-CSF receptor.
• Long-term follow-up (74 weeks) to assess safety and efficacy profiles.
• Monitoring of acute phase reactants and assessment of efficacy in TNF-inhibitor resistant patients.

Main Results:

• Mavrilimumab demonstrated an acceptable and sustained safety and tolerability profile over 74 weeks.
• Rapid and sustained efficacy was observed, with normalization of acute phase reactants.
• Preclinical studies suggest a TNF-independent mechanism, potentially blocking GM-CSF and IL-17 signaling.

Conclusions:

• Targeting GM-CSF, exemplified by mavrilimumab, offers a promising therapeutic strategy for rheumatoid arthritis.
• Mavrilimumab shows potential as an alternative biologic agent, particularly for patients resistant to TNF inhibitors.
• Further investigation into GM-CSF blocking agents in diverse RA subgroups is warranted.